• Molecular NameClindamycin
  • SynonymClindamicina [INN-Spanish]; clindamycin; Clindamycin Hcl; Clindamycin Hydrochloride; Clindamycin Phosphate; Clindamycine [French]; Clindamycine [INN-French]; Clindamycinum [INN-Latin]
  • Weight424.99
  • Drugbank_IDDB01190
  • ACS_NO18323-44-9
  • Show 2D model
  • LogP (experiment)2.16
  • LogP (predicted, AB/LogP v2.0)2.02
  • pka7.7
  • LogD (pH=7, predicted)1.42
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.55
  • LogSw (predicted, AB/LogsW2.0)14.67
  • Sw (mg/ml) (predicted, ACD/Labs)4.67
  • No.of HBond Donors4
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds7
  • TPSA127.56
  • StatusFDA approved
  • AdministrationOral, topical, IV, intravaginal
  • PharmacologyA lincosamide antibiotic.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability87.0
  • Protein binding93.6
  • Volume of distribution (VD)1.1 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic
  • Half life2.9 h
  • ExcretionBiliary and renal (around 20%)
  • Urinary Excretion13
  • Clerance4.7 ml/min/kg
  • ToxicityOrally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
  • LD50 (rat)LD50>5000
  • LD50 (mouse)N/A